Ascendis Pharma A/S (ASND) News Today $139.70 +3.32 (+2.43%) (As of 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period 7,376 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Acquired by Public Employees Retirement System of OhioPublic Employees Retirement System of Ohio purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,376 shares ofDecember 20 at 4:10 AM | marketbeat.comBrokerages Set Ascendis Pharma A/S (NASDAQ:ASND) PT at $191.77December 20 at 3:53 AM | americanbankingnews.comAscendis Pharma A/S Announces U.S. Commercial Availability of YORVIPATH® for Hypoparathyroidism TreatmentDecember 19, 2024 | quiverquant.comYORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in AdultsDecember 19, 2024 | finance.yahoo.comYORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in AdultsDecember 19, 2024 | globenewswire.comAscendis Pharma’s Promising Growth Prospects: Buy Rating Backed by Positive Clinical Results and Expected Share Price SurgeDecember 17, 2024 | markets.businessinsider.comAscendis Pharma (ASND) Gets a Buy from Stifel NicolausDecember 17, 2024 | markets.businessinsider.comAscendis Pharma: New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26December 16, 2024 | finanznachrichten.deAnalysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)December 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioLife Solutions (BLFS) and Delcath Systems (DCTH)December 16, 2024 | markets.businessinsider.comNew InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26December 16, 2024 | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Short Interest UpdateAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 3,770,000 shares, an increase of 5.6% from the November 15th total of 3,570,000 shares. Based on an average daily volume of 587,700 shares, the short-interest ratio is presently 6.4 days.December 16, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and twelDecember 15, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Nomura Asset Management Co. Ltd.Nomura Asset Management Co. Ltd. lifted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 42.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,000 shares oDecember 15, 2024 | marketbeat.comFDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon hGH for the Treatment of Adults with Growth Hormone DeficiencyDecember 14, 2024 | finanznachrichten.deAscendis Pharma A/S (NASDAQ:ASND) Stock Holdings Increased by Exome Asset Management LLCExome Asset Management LLC raised its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 119.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 43,849 shares of the biotechnology comDecember 14, 2024 | marketbeat.comY Intercept Hong Kong Ltd Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)Y Intercept Hong Kong Ltd bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,931 shares of the biotechnology company's stock, vDecember 13, 2024 | marketbeat.comAscendis Pharma announces FDA to review TransCon hGH sBLADecember 13, 2024 | markets.businessinsider.comAscendis Pharma’s TransCon hGH Receives FDA Review for Adult UseDecember 13, 2024 | markets.businessinsider.comAscensis Pharma Says FDA Will Review Application for Adult Treatment of Growth Hormone DeficiencyDecember 12, 2024 | marketwatch.comAscendis sBLA for Transcon hGH accepted by FDADecember 12, 2024 | msn.comFDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyDecember 12, 2024 | globenewswire.comEr-Kim and Ascendis’ endocrine therapy agreement extended in EurasiaDecember 11, 2024 | msn.comEr-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian MarketsDecember 10, 2024 | globenewswire.comFrazier Life Sciences Management L.P. Invests $19.91 Million in Ascendis Pharma A/S (NASDAQ:ASND)Frazier Life Sciences Management L.P. purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 133,333 shares of the biDecember 10, 2024 | marketbeat.comGroupama Asset Managment Acquires Shares of 404,000 Ascendis Pharma A/S (NASDAQ:ASND)Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 404,000 shares of the biotechnology comDecember 10, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Holdings Lowered by Wellington Management Group LLPWellington Management Group LLP trimmed its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 51.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,261,480 shares of the biotechnology company's stock after sDecember 9, 2024 | marketbeat.comXTX Topco Ltd Acquires Shares of 11,333 Ascendis Pharma A/S (NASDAQ:ASND)XTX Topco Ltd bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,333 shares of the biotechnology company's stocDecember 8, 2024 | marketbeat.comRA Capital Management L.P. Sells 397,972 Shares of Ascendis Pharma A/S (NASDAQ:ASND)RA Capital Management L.P. reduced its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,710,428 shares of the biotechnology company'sDecember 5, 2024 | marketbeat.comMaven Securities LTD Buys Shares of 50,000 Ascendis Pharma A/S (NASDAQ:ASND)Maven Securities LTD purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 50,000 shares of the biotechnology companDecember 4, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Cinctive Capital Management LPCinctive Capital Management LP lowered its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 41.8% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,271 shares of the biotechnology company's stock aftDecember 4, 2024 | marketbeat.com20,300 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Bought by Erste Asset Management GmbHErste Asset Management GmbH purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 20,300 shares of the biotechnology comDecember 3, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Has $10.65 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)The Manufacturers Life Insurance Company increased its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 49.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,307 shares of the biotechnology coDecember 3, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Fred Alger Management LLCFred Alger Management LLC decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 15.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 258,210 shares of the biotechNovember 29, 2024 | marketbeat.comVestal Point Capital LP Sells 500,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Vestal Point Capital LP cut its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 66.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 250,000 shares of the biotechnology company's stock after sellingNovember 29, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Spyglass Capital Management LLCSpyglass Capital Management LLC lowered its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.5% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 652,841 shares of the biotechnology company's stock after selling 10,047 shares during thNovember 29, 2024 | marketbeat.comSummit Partners Public Asset Management LLC Trims Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Summit Partners Public Asset Management LLC reduced its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 46.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 55,101 shares of the biotechnology company's stock aftNovember 29, 2024 | marketbeat.comFmr LLC Reduces Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Fmr LLC trimmed its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,907,846 shares of the biotechnology company's stock after selling 14,709 sharNovember 29, 2024 | marketbeat.comAcuta Capital Partners LLC Buys New Position in Ascendis Pharma A/S (NASDAQ:ASND)Acuta Capital Partners LLC purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 21,000 shares of the biotechnology company's stock, valued at approximately $3,13November 28, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Purchased by Loomis Sayles & Co. L PLoomis Sayles & Co. L P increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 35.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 184,623 shares of the biotechnology company's stock afterNovember 26, 2024 | marketbeat.comWestfield Capital Management Co. LP Has $766.52 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)Westfield Capital Management Co. LP boosted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,133,766 shares of the biotechnologyNovember 24, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Raises Position in Ascendis Pharma A/S (NASDAQ:ASND)Massachusetts Financial Services Co. MA raised its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 9.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,866,986 shares of the biotechnology compaNovember 23, 2024 | marketbeat.comValence8 US LP Invests $685,000 in Ascendis Pharma A/S (NASDAQ:ASND)Valence8 US LP purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,585 shares of the biotechnology company's stock, valueNovember 22, 2024 | marketbeat.comCan BioMarin Stock Live Up to Wall Street’s High Expectations? (ASND)BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?November 22, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the thirteen ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and twelve have assigned aNovember 20, 2024 | marketbeat.comStockNews.com Upgrades Ascendis Pharma A/S (NASDAQ:ASND) to HoldStockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday.November 20, 2024 | marketbeat.comAscendis Pharma: Strategic Expansion and Product Launches Drive Future Growth, Outperform Rating ReaffirmedNovember 19, 2024 | markets.businessinsider.comFirst Turn Management LLC Trims Position in Ascendis Pharma A/S (NASDAQ:ASND)First Turn Management LLC reduced its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 19.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 150,593 shares of the biotechnology company's stock after selling 35,988 shares duNovember 19, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Sees Large Growth in Short InterestAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 3,410,000 shares, a growth of 5.6% from the October 15th total of 3,230,000 shares. Based on an average daily volume of 634,100 shares, the short-interest ratio is currently 5.4 days.November 17, 2024 | marketbeat.comAscendis Pharma price target lowered to $153 from $160 at TD CowenNovember 15, 2024 | markets.businessinsider.com Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address No one’s talking about these Trump trades (Ad)As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.” Go here to see how you can start accessing these opportunities today ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼0.730.59▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼106▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News Today TEVA News Today BGNE News Today MRNA News Today VTRS News Today SMMT News Today GMAB News Today RDY News Today CTLT News Today SRPT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 12/23/2024 by MarketBeat.com Staff From Our Partners24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ASND Stock Alerts